PerkinElmer, Inc.
About PerkinElmer, Inc.
734 articles with PerkinElmer, Inc.
-
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022
1/11/2022
PerkinElmer, Inc. today announced that it anticipates reported and organic revenue growth for the fourth quarter of 2021 of approximately -1% and -12%, respectively, versus the same period a year ago.
-
PerkinElmer to Present Virtually at J.P. Morgan Healthcare Conference
12/21/2021
PerkinElmer, Inc. today announced that the Company will present virtually at the annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:15 a.m. ET.
-
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays
11/29/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of Omicron (B.1.1.529), a variant of concern that was recently identified by the World Health Organization (WHO).
-
PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management
11/22/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its PKeye™ Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows in real-time.
-
PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021
11/16/2021
PerkinElmer, Inc. today announced that the Company will present at the Evercore ISI 4th Annual HealthCONx Conference 2021 on Wednesday, December 1, 2021 at 10:30 a.m. ET.
-
PerkinElmer to Present at 2021 Stifel Healthcare Conference
11/5/2021
PerkinElmer, Inc. today announced that the Company will present at the virtual 2021 Stifel Healthcare Conference on Tuesday, November 16, 2021 at 8:40 a.m. ET.
-
PerkinElmer Announces Financial Results for the Third Quarter of 2021
11/2/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the third quarter ended October 3, 2021.
-
PerkinElmer Releases 2021 Corporate Social Responsibility Report
11/1/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes the latest achievements of its environmental, social and governance (ESG) program.
-
PerkinElmer Board Declares Quarterly Dividend - Oct 27, 2021
10/27/2021
The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock October 27, 2021.
-
PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis
10/18/2021
PerkinElmer, Inc. (NYSE: PKI) and Honeycomb Biotechnologies, Inc., announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis.
-
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
10/7/2021
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.
-
PerkinElmer’s Horizon Discovery CHOSOURCE™ Platform Expanding To Include CHO-K1 ADCC+ Expression Cell Line for Development of Therapeutic Antibodies in Oncology, Infectious Disease and Autoimmune Conditions
10/6/2021
PerkinElmer Inc today announced that its Horizon Discovery CHOSOURCE™ platform is expanding to include a new expression cell line, CHO-K1 ADCC+ .
-
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
9/17/2021
PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.
-
PerkinElmer to Present at 2021 Baird Global Healthcare Conference
8/24/2021
PerkinElmer, Inc, today announced that the Company will present at the virtual Baird Global Healthcare Conference on Tuesday, September 14, 2021 at 10:50 a.m. ET.
-
PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins
8/19/2021
PerkinElmer, Inc today announced the launch of its MaxSignal® Mycotoxin Automation Bundle .
-
PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits
7/28/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced four new ready-to-use AlphaLISA® KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers.
-
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
7/26/2021
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.
-
PerkinElmer Announces Financial Results for the Second Quarter of 2021
7/26/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021.
-
It's been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
-
Ampersand Completes Sale of Portfolio Company Nexcelom Bioscience to PerkinElmer
6/25/2021
Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.